Autoimmune Diseases Fact Sheet III-1
Table 20: Prevalence of Key Autoimmune Diseases in the US
for 2006 (in Millions) (includes corresponding Graph/Chart) III-2
Market Trends III-2
Biologic Drugs Lead the Fray III-2
Biologics To Add Further Impetus to the Market III-2
Rheumatoid Arthritis Drugs Lead the Market III-3
Enbrel and Humira Continue to Gain Share in the Anti-TNF
Market III-3
Increased Incidence and Rise in Drug Prices to Drive Growth
in MS Market III-3
Table 21: US Multiple Sclerosis Drug Market (2006):
Percentage Breakdown of Number of Dispensed Prescriptions
for Avonex, Copaxone, Rebif, Betaseron and Tysabri
(includes corresponding Graph/Chart) III-4
Incidence of Type 1 Diabetes Mellitus Endemic in White Youth III-4
Lialda's Share Gaining Momentum in Ulcerative Colitis Drugs
Market III-4
Key Ulcerative Colitis Drugs Market in the US (2006) III-5
Table 22: US Ulcerative Colitis Drugs Market (2007 &
2008): Percentage Breakdown of Prescriptions Dispensed
Ranked by Leading Drugs for Asacol, Pentasa, Lialda,
Canasa, Sulphasalazine, Colazal, Other Drugs and Generics
(includes corresponding Graph/Chart) III-5
Product Launches/ Approvals III-6
Strategic Corporate Developments III-9
Key Players III-28
B.Market Analytics III-36
Table 23: US Recent Past, Current & Future Analysis for
Autoimmune Disease Therapeutics by Disease Segment -
Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Crohn's
Disease (Biologics) and Other Autoimmune Diseases
Independently Analyzed with Annual Sales in US$ Billion for
Years 2006 through 2015 (includes corresponding Graph/Chart) III-36
Table 24: US 10-year Perspective for Autoimmune Disease
Therapeutics by Dis
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |